Active In-House Studies at Virginia Hospital Center
Investigator: Walter L. Atiga, M.D.
Mentor Protocol Title: ENSURE Cardiac Resynchronization Therapy Study.
Investigator: Walter L. Atiga, M.D.
Guidant Protocol Title: REFLEX Study: ENDOTAK RELIANCE G Evaluation of Handling and Electrical
Performance.
Investigator: John R. Garrett, M.D.
Protocol Number: Nabi Biopharmaceuticals Protocol Nabi-1366.
Protocol Title: A multicenter, randomized, placebo-controlled, double-blinded study to evaluate
safety and immunogenicity of StaphVAX, a bivalent staphylococcus aureus glycoconjugate vaccine in adult
patients undergoing cardiovascular surgery.
Investigator: John R. Garrett, M.D.
Protocol Number: Alexion and Proctor & Gamble Protocol 2003141
Protocol Title: A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of
2 mg/kg bolus plus 24-hour 0.5 mg/kg/hr infusion pexelizumab in patients undergoing coronary artery
bypass grafting with cardiopulmonary bypass.
Investigator: Ramanath Gopalan, M.D.
Protocol Number: Eli Lilly Protocol F1D-US-HGLS.
Protocol Title: Olanzipineversus Aripiprazole in the treatment of acutely ill patients with
schizophrenia.
Investigator: Michael P. Notarianni, M.D.
Protocol Number: AstraZeneca Protocol 4522US/0001
Protocol Title: A 12-week, randomized, open-label, 3-arm, parallel group, multicenter, phase IIIb
study comparing the efficacy and safety of Rosuvastatin 20mg and 40mg with that of Atorvastatin 80mg in
subjects with acute coronary syndromes [LUNAR].
Investigator: Talal A. Munasifi, M.D.
Protocol Number: WIRB 96564
Protocol Title: Adjunct study for Mentor H/S silicone gel-filled mammary prosthesis.
Investigator: Dr. Tariq Shahab, M.D.
Protocol Number: WIRB 1585
Protocol Title: Safety and efficacy of Jomed Jostent coronary stent-graft in the treatment of free
perforations during percutaneous coronary interventions.
Investigator: Ramanath Gopalan, M.D.
Protocol Number: Pfizer A1281110
Protocol Title: A Four-Week Double-Blind Multi-Center Study Comparing the Efficacy and
Safety of Ziprasidone to Aripiprazole in Subjects with Scizophrenia or Schizoaffective Disorder Needing
Inpatient Care
Investigator: Steven K. Neufeld, M.D.
Protocol Number: 1
Protocol Title: The Foot and Ankle Post-op Pain Trial (the FA-POP trial): A Patient
Oriented Study
Investigator: Ramanath Gopalan, M.D.
Protocol Number: Pfizer and Organon A7501005
Protocol Title: A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the
Safety and Efficacy of Sublingual Azenapine vs. Olanzapine and Placebo in In-Patients with an Acute
Manic Episode.
Investigator: Ramanath Gopalan, M.D.
Protocol Number: Pfizer and Organon A7501006
Protocol Title: A Double-Blind, 9-Week Extension Study Evaluating the Safety and Maintenance
of Effect of Azenapine vs. Olanzapine in the Treatment of Subjects with Acute Mania.
Investigator: Ramanath Gopalan, M.D.
Protocol Number: Solvay S1543004
Protocol Title: A Randomized, Double-Blind, Olanzapine-Referenced, Parallel-Group Safety and
Efficacy Study of Flexible Doses of Bifeprunox in the Long-Term Treatment of Schizophrenia (Extension
of Protocol S1543003)
Investigator: Rita Wong, EdD., PT
Protocol Title: Barriers and Facilitators to the Diffusion of a Comprehensive Balance and
Falls Prevention Program within a Hospital.
Investigator:Ramanath Gopalan, M.D.
Protocol Number: Pfizer and Organon 041023
Protocol Title:AMulticenter, Randomized, Double-Blind, Fixed -Dose, 6-Week Trial of
Efficacy and Safety of Asenapine Compared with Placebo Using Haloperidol Positive Control in Subjects
with an Acute Exacerbation of Schizophrenia
Investigator:Ramanath Gopalan, M.D.
Number: Pfizer and Organon 04513
Protocol Title: A Multicenter, Double-Blind, Flexible-Dose, Long-Term Extension Trial
6-Week Trial of the Safety and Maintenance of Effect of Asenapine Using Haloperidol Positive Control in
Subjects Who Complete Protocol 041023
Investigator: Walter Atiga
Title: Medtronic Partners HF
Multi-Site Program to Access and Review Trending Information and Evaluate CoR Relation to
Symptoms in Patients with Heart Failure
Investigator: Charanjit S. Khurana, M.D.
Number: Pfizer A7641006
Title: A Phase 2 Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study of the Safety,
Tolerability, Pharmacokinetics, and Pharmacodynamics of ET-00216 in Patients with Acute Coronary
Syndromes
Investigator: David Duhamel, M.D.
Number Asthmatx 04-02
Protocol Title: Safety and Effectiveness of the Alair System for the Treatment of Asthma: A
Muticenter Randomized Clinical Trial (Asthma Intervention Research (AIR2) Trial)
Investigator: Ramanath Gopalan, M.D.
Number: GlaxoSmithKline NAA104606
Protocol Title: A Multicenter, Double-Blind, Double Dummy, Placebo-Controlled, Randomized,
Adaptive, Dose-Range Study to Evaluate the Safety and Efficacy of SB-773812 Administered Once daily for
12 Weeks in Adults with Schizophrenia"